A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce
Tekijät: Manzoni, Paolo; Baraldi, Eugenio; Midulla, Fabio; Claris, Olivier; Dessardo, Sandro; Heikkinen, Terho; Thwaites, Richard; Paes, Bosco; Carbonell-Estrany, Xavier; Dobryanskyy, Dmytro; Cetinkaya, Merih; Al Harbi, Adel S.; Kang, Ji-Man; Goh Eng Neo, Anne; Chi, Hsin; Sant'Anna, Guilherme; Villa Guillen, Monica; Mariani, Gonzalo Luis; Safadi, Marco Aurelio Palazzi; Urzua, Soledad; Zar, Heather J.; Goussard, Pierre; Rodgers-Gray, Barry; Waghorne, Nicola; Sanchez Luna, Manuel
Kustantaja: Oxford University Press (OUP)
Kustannuspaikka: CARY
Julkaisuvuosi: 2025
Journal: Open Forum Infectious Diseases
Tietokannassa oleva lehden nimi: Open Forum Infectious Diseases
Lehden akronyymi: OPEN FORUM INFECT DI
Artikkelin numero: ofaf396
Vuosikerta: 12
Numero: 7
Sivujen määrä: 16
ISSN: 2328-8957
eISSN: 2328-8957
DOI: https://doi.org/10.1093/ofid/ofaf396
Verkko-osoite: https://doi.org/10.1093/ofid/ofaf396
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/499701893
Background: Long-acting monoclonal antibodies (LAmAbs) could dramatically reduce the respiratory syncytial virus (RSV) disease burden in children if implemented using clear, evidence-based recommendations.
Methods: The ARMADA Taskforce-an international, multidisciplinary expert panel-undertook a systematic review to develop LAmAbs consensus recommendations for RSV disease prevention in children.
Results: The Taskforce recommends LAmAbs for all infants aged <8 months in the absence of maternal RSV vaccination, preterm infants (<37 weeks' gestational age) aged <12 months, and children <24 months with high-risk conditions. Seasonal LAmAb administration is recommended, although in RSV-endemic countries decisions should be made locally concerning administration year-round or with peak RSV incidences.
Conclusions: The Taskforce strongly endorses LAmAbs implementation based on their efficacy, effectiveness, and public health impact. These recommendations provide a blueprint to inform guidelines worldwide. Wider equitable access to LAmAbs at affordable prices, especially in low- and middle-income countries is needed to reduce the childhood RSV burden.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
Financial support for this study was provided by Sanofi and AstraZeneca. The sponsors had no role in the selection of ARMADA participants, the preparation of the manuscript, or the decision to submit for publication.
